LEVODOPA

Levodopa (L-DOPA) is a precursor to dopamine, widely used in the treatment of Parkinson’s disease, Parkinsonian syndromes, and dopamine-responsive movement disorders. It crosses the blood-brain barrier and is converted into dopamine, restoring deficient neurotransmitter levels and improving motor function, reducing tremors, rigidity, and bradykinesia in patients.

At Bluepill Express, we manufacture and export pharmaceutical-grade Levodopa API under WHO-GMP, ISO, and cGMP-certified facilities. Our API complies with IP, BP, USP, and EP standards, ensuring high purity, consistent particle size, and excellent stability, making it suitable for tablets, capsules, and combination formulations (e.g., Levodopa + Carbidopa).

Our Levodopa API undergoes stringent quality control testing, including HPLC, IR spectroscopy, and microbial analysis, guaranteeing safety and efficacy for global pharmaceutical applications.

Pharmacological Information:

• Therapeutic Class: Anti-Parkinson Agent
• Pharmacological Category: Dopamine Precursor
• CAS Number: 59-92-7
• Molecular Formula: C9H11NO4
• Molecular Weight: 197.19 g/mol
• Appearance: White to off-white crystalline powder
• Solubility: Freely soluble in water, slightly soluble in ethanol
• Melting Point: 282°C – 283°C (decomposes)
• Storage: Store in a cool, dry place, below 25°C, protected from light

Mode of Action:

Levodopa is converted into dopamine in the brain, compensating for the dopamine deficiency in the striatum of Parkinson’s disease patients. This restores normal motor control, improves coordination, and alleviates the characteristic symptoms of Parkinsonism. When co-administered with Carbidopa, peripheral metabolism is reduced, increasing the availability of Levodopa in the CNS and reducing side effects like nausea.

Applications and Uses:

• Treatment of Parkinson’s Disease – Improves tremor, rigidity, and bradykinesia
• Parkinsonian Syndromes – Secondary Parkinsonism and post-encephalitic Parkinsonism
• Dopamine-Responsive Movement Disorders – Such as Dopa-Responsive Dystonia
• Combination Therapy – With Carbidopa or Benserazide for enhanced efficacy

Technical Specifications:

• Assay (Purity): ≥ 99.5%
• Identification: IR spectrum matches reference standard
• Loss on Drying: ≤ 0.5%
• Residue on Ignition: ≤ 0.1%
• Heavy Metals: ≤ 10 ppm
• Specific Optical Rotation: +13° to +17°
• Related Substances: ≤ 0.2% (individual impurity)
• Microbial Limits: Complies with pharmacopeial specifications

Manufacturing & Quality Assurance – Bluepill Express:

• Produced under WHO-GMP, ISO 9001:2015, and cGMP-certified facilities
• Micronized API ensures uniform formulation and optimal bioavailability
• COA, MSDS, and TDS provided with all shipments
• Pharmacopeial compliance: IP / BP / USP / EP
• HPLC-tested for purity and stability
• Suitable for tablets, capsules, and combination formulations

---

Packaging & Export Details:

• Available Packs: 1 kg, 5 kg, 10 kg, 25 kg HDPE drums with inner liner
• Shelf Life: 36 months from manufacturing date
• Labeling: Export-compliant, with batch number and origin
• Export Markets: Africa, Asia, Europe, Middle East, Latin America
• Documentation Provided:
  • Certificate of Analysis (COA)
  • Material Safety Data Sheet (MSDS)
  • Technical Data Sheet (TDS)
  • Stability Data (on request)
  • Non-GMO & Allergen-Free Declarations